A
66.00
-0.51 (-0.77%)
| Previous Close | 66.51 |
| Open | 64.90 |
| Volume | 499,973 |
| Avg. Volume (3M) | 757,876 |
| Market Cap | 3,637,042,176 |
| Price / Sales | 46.92 |
| Price / Book | 8.79 |
| 52 Weeks Range | |
| Earnings Date | 19 Aug 2025 - 3 Sep 2025 |
| Profit Margin | -211.46% |
| Operating Margin (TTM) | -847.56% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | -79.30% |
| Total Debt/Equity (MRQ) | 12.76% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -114.70 M |
| Levered Free Cash Flow (TTM) | -10.43 M |
| Return on Assets (TTM) | -16.69% |
| Return on Equity (TTM) | -35.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Arcellx, Inc. | Bearish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.90 |
|
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 14.50% |
| % Held by Institutions | 102.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilead Sciences, Inc. | 31 Mar 2025 | 6,720,803 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 115.00 (HC Wainwright & Co., 74.24%) | Buy |
| Median | 110.00 (66.67%) | |
| Low | 93.00 (Scotiabank, 40.91%) | Buy |
| Average | 106.00 (60.61%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 63.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 17 Jun 2025 | 110.00 (66.67%) | Buy | 66.00 |
| HC Wainwright & Co. | 16 Jun 2025 | 115.00 (74.24%) | Buy | 66.00 |
| Scotiabank | 09 May 2025 | 93.00 (40.91%) | Buy | 57.55 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PATEL KAVITA | - | 66.61 | -1,500 | -99,915 |
| Aggregate Net Quantity | -1,500 | |||
| Aggregate Net Value ($) | -99,915 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 66.61 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PATEL KAVITA | Director | 10 Jun 2025 | Automatic sell (-) | 1,500 | 66.61 | 99,915 |
| PATEL KAVITA | Director | 10 Jun 2025 | Option execute | 1,500 | - | - |
| Date | Type | Details |
|---|---|---|
| 21 May 2025 | Announcement | Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 |
| 14 May 2025 | Announcement | Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma |
| 08 May 2025 | Announcement | Arcellx Provides First Quarter 2025 Financial Results and Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |